Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2018

  • ID: 4473132
  • Drug Pipelines
  • 116 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Bioverativ Inc
  • Dova Pharmaceuticals Inc
  • Hansa Medical AB
  • Novartis AG
  • Principia Biopharma Inc
  • MORE
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H1 2018, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 4, 8, 4, 2 and 7 respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Bioverativ Inc
  • Dova Pharmaceuticals Inc
  • Hansa Medical AB
  • Novartis AG
  • Principia Biopharma Inc
  • MORE
Introduction

Report Coverage

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development

3SBio Inc

Amgen Inc

arGEN-X BV

Bioverativ Inc

Bristol-Myers Squibb Co

CSL Ltd

Dova Pharmaceuticals Inc

Enzene Biosciences Ltd

Fujifilm Holdings Corporation

Genosco Inc

Hansa Medical AB

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Pharmagenesis Inc

Principia Biopharma Inc

Protalex Inc

Rigel Pharmaceuticals Inc

UCB SA

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles

avatrombopag - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIVV-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-730 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Chemotherapy Induced Thrombocytopenia and Idiopathic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FF-10102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostamatinib disodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-2045 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hetrombopag Olamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLM-465 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

letolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-281 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1650 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHN-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRTX-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKIO-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thrombopoietin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veltuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones

Featured News & Press Releases

Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference

Jan 03, 2018: Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)

Dec 04, 2017: Dova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual Meeting

Nov 16, 2017: New UCB research published in Science Translational Medicine

Nov 10, 2017: Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura

Oct 30, 2017: Argenx Launches Phase I Trial with Subcutaneous Formulation of ARGX-

Oct 18, 2017: Novartis drug Revolade shows long-term disease control for chronic/persistent immune thrombocytopenia

Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP

Sep 20, 2017: Argenx Reaches 50% Enrollment in Phase 2 Clinical Trial of ARGX-113 in Immune Thrombocytopenia

Aug 30, 2017: Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference

Jun 21, 2017: Amgen To Present Data on Nplate At 22nd Congress of the European Hematology Association

Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP

Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States

Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP

Mar 31, 2017: argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bioverativ Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by CSL Ltd, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Dova Pharmaceuticals Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Enzene Biosciences Ltd, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Fujifilm Holdings Corporation, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pharmagenesis Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Principia Biopharma Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals Inc, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by UCB SA, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H1 2018

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • Amgen Inc
  • arGEN-X BV
  • Bioverativ Inc
  • Bristol-Myers Squibb Co
  • CSL Ltd
  • Dova Pharmaceuticals Inc
  • Enzene Biosciences Ltd
  • Fujifilm Holdings Corporation
  • Genosco Inc
  • Hansa Medical AB
  • Immunomedics Inc
  • Intas Pharmaceuticals Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Momenta Pharmaceuticals Inc
  • Novartis AG
  • Pfizer Inc
  • Pharmagenesis Inc
  • Principia Biopharma Inc
  • Protalex Inc
  • Rigel Pharmaceuticals Inc
  • UCB SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll